JP2012506451A5 - - Google Patents

Download PDF

Info

Publication number
JP2012506451A5
JP2012506451A5 JP2011533341A JP2011533341A JP2012506451A5 JP 2012506451 A5 JP2012506451 A5 JP 2012506451A5 JP 2011533341 A JP2011533341 A JP 2011533341A JP 2011533341 A JP2011533341 A JP 2011533341A JP 2012506451 A5 JP2012506451 A5 JP 2012506451A5
Authority
JP
Japan
Prior art keywords
fluid
cell
oxygen
item
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011533341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506451A (ja
JP5688370B2 (ja
Filing date
Publication date
Priority claimed from US12/258,210 external-priority patent/US20090274730A1/en
Application filed filed Critical
Priority claimed from PCT/US2009/061710 external-priority patent/WO2010048425A1/en
Publication of JP2012506451A publication Critical patent/JP2012506451A/ja
Publication of JP2012506451A5 publication Critical patent/JP2012506451A5/ja
Application granted granted Critical
Publication of JP5688370B2 publication Critical patent/JP5688370B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011533341A 2008-10-22 2009-10-22 胸腺間質性リンパ球新生因子（ｔｓｌｐ）媒介状態を治療するための組成物および方法 Expired - Fee Related JP5688370B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10748008P 2008-10-22 2008-10-22
US10745308P 2008-10-22 2008-10-22
US61/107,453 2008-10-22
US61/107,480 2008-10-22
US12/258,210 2008-10-24
US12/258,210 US20090274730A1 (en) 2007-10-25 2008-10-24 Compositions and methods for treating inflammation
PCT/US2009/061710 WO2010048425A1 (en) 2008-10-22 2009-10-22 Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014246760A Division JP2015044869A (ja) 2008-10-22 2014-12-05 胸腺間質性リンパ球新生因子（ｔｓｌｐ）媒介状態を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2012506451A JP2012506451A (ja) 2012-03-15
JP2012506451A5 true JP2012506451A5 (https=) 2012-12-06
JP5688370B2 JP5688370B2 (ja) 2015-03-25

Family

ID=42119683

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011533355A Expired - Fee Related JP5688371B2 (ja) 2008-10-22 2009-10-22 マトリクスメタロプロテイナーゼ９（ｍｍｐ９）媒介状態を治療するための組成物および方法
JP2011533341A Expired - Fee Related JP5688370B2 (ja) 2008-10-22 2009-10-22 胸腺間質性リンパ球新生因子（ｔｓｌｐ）媒介状態を治療するための組成物および方法
JP2014246760A Withdrawn JP2015044869A (ja) 2008-10-22 2014-12-05 胸腺間質性リンパ球新生因子（ｔｓｌｐ）媒介状態を治療するための組成物および方法
JP2014246753A Withdrawn JP2015044868A (ja) 2008-10-22 2014-12-05 マトリクスメタロプロテイナーゼ９（ｍｍｐ９）媒介状態を治療するための組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011533355A Expired - Fee Related JP5688371B2 (ja) 2008-10-22 2009-10-22 マトリクスメタロプロテイナーゼ９（ｍｍｐ９）媒介状態を治療するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014246760A Withdrawn JP2015044869A (ja) 2008-10-22 2014-12-05 胸腺間質性リンパ球新生因子（ｔｓｌｐ）媒介状態を治療するための組成物および方法
JP2014246753A Withdrawn JP2015044868A (ja) 2008-10-22 2014-12-05 マトリクスメタロプロテイナーゼ９（ｍｍｐ９）媒介状態を治療するための組成物および方法

Country Status (9)

Country Link
EP (2) EP2364154A4 (https=)
JP (4) JP5688371B2 (https=)
CN (2) CN102256607B (https=)
AU (2) AU2009308362B2 (https=)
BR (2) BRPI0920430A2 (https=)
CA (2) CA2741336A1 (https=)
IL (2) IL212277A0 (https=)
MX (2) MX2011004233A (https=)
WO (2) WO2010048425A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
AU2007308838B2 (en) 2006-10-25 2014-03-13 Revalesio Corporation Mixing device and output fluids of same
US8597689B2 (en) 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
AU2009241365B2 (en) * 2008-04-28 2015-01-22 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US8980325B2 (en) 2008-05-01 2015-03-17 Revalesio Corporation Compositions and methods for treating digestive disorders
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
BR112012028540A2 (pt) 2010-05-07 2016-07-26 Revalesio Corp composições e métodos para melhorar desempenho fisiológico e tempo de recuperação
JP2013533320A (ja) 2010-08-12 2013-08-22 レバレジオ コーポレイション タウオパチーを治療するための組成物および方法
US20120263764A1 (en) * 2011-04-13 2012-10-18 Revalesio Corporation Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease
CN102268069B (zh) * 2011-07-01 2012-11-28 中国药科大学 基质金属蛋白酶-9多肽抑制剂4及其应用
CN102250213B (zh) * 2011-07-01 2012-11-07 中国药科大学 基质金属蛋白酶-9多肽抑制剂3及其应用
CN102268070B (zh) * 2011-07-01 2012-11-28 中国药科大学 基质金属蛋白酶-9多肽抑制剂2及其应用
KR101492435B1 (ko) * 2012-12-28 2015-02-10 고려대학교 산학협력단 ＨＩＦ­１α ｓｉＲＮＡ를 유효성분으로 함유하는 ＴＳＬＰ에 의해 매개되는 질환 예방 또는 치료용 약제학적 조성물
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CN105477628B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 抗癌组合物及其用途
CN106943593A (zh) * 2017-03-24 2017-07-14 浙江中医药大学 抗tslp抗体在制备防治慢性瘙痒药物中的应用
EP3645035A4 (en) * 2017-06-27 2021-04-07 Translational Sciences, Inc. INHIBITION OF VASCULAR MATRIX METALLOPROTEINASE 9 TO TREAT ISCHEMIC DAMAGE
MX2021014028A (es) * 2019-05-17 2022-02-21 Univ Pennsylvania Métodos y composiciones para tratar obesidad y/o trastornos de la piel.
CN114887053B (zh) * 2019-11-29 2026-04-24 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
WO2025076280A1 (en) 2023-10-05 2025-04-10 Ashibio, Inc. Methods and compositions for treating mmp-9 mediated disorders
WO2026076260A1 (en) 2024-10-03 2026-04-09 Ashibio, Inc. Methods and compositions for mmp-9 inhibition for use with non-genetic heterotopic ossification disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100811B1 (en) * 1998-07-28 2007-07-04 The Regents Of The University Of California Nucleic acids encoding a g-protein coupled receptor involved in sensory transduction
RU2271825C2 (ru) * 1999-07-21 2006-03-20 Омерос Корпорейшн Растворы и способы ингибирования боли, воспаления и разрушения хряща
US20040235732A1 (en) * 2000-11-03 2004-11-25 Qun-Yong Zhou Method for modulating angiogenesis using prokineticin receptor antagonists
US20030232114A1 (en) * 2002-06-13 2003-12-18 Nikola Dekleva Method for liquid enrichment with oxygen and applications of enriched liquids
AU2002321678A1 (en) * 2002-09-09 2004-03-29 Boros Béla Oxygen-enriched water, treated within a magnetic field and heavy water
US20070077553A1 (en) * 2003-10-30 2007-04-05 Rosetta Genomics Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
US8206704B2 (en) * 2003-02-10 2012-06-26 Thomas Jefferson University Use of GCC ligands
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7393924B2 (en) * 2004-01-06 2008-07-01 Franco Vitaliano Smart bio-nanoparticle elements
KR100583430B1 (ko) * 2004-03-08 2006-05-24 양경숙 차륜 가변형 스쿠터
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
WO2008018932A2 (en) * 2006-05-01 2008-02-14 The Board Of Trustees Of The Leland Stanford Junior University Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
US20080014278A1 (en) * 2006-06-30 2008-01-17 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
AU2007308838B2 (en) * 2006-10-25 2014-03-13 Revalesio Corporation Mixing device and output fluids of same
JP5491185B2 (ja) * 2006-10-25 2014-05-14 リバルシオ コーポレイション 傷のケアおよび処置の方法
US8597689B2 (en) * 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
EP2215260A4 (en) * 2007-10-25 2011-04-20 Revalesio Corp COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION
AU2009241365B2 (en) * 2008-04-28 2015-01-22 Revalesio Corporation Compositions and methods for treating multiple sclerosis

Similar Documents

Publication Publication Date Title
JP2012506451A5 (https=)
JP2011500854A5 (https=)
JP2011523627A5 (https=)
JP2014511879A5 (https=)
JP2011500847A5 (https=)
JP2012525396A5 (https=)
CN102257130B (zh) 用于治疗胸腺基质淋巴细胞生成素(tslp)介导的病症的组合物和方法
CA2798127A1 (en) Methods and compositions for protecting against neurotoxic agents
Vehring et al. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers
HRP20200298T1 (hr) Pripravci za respiratorno davanje aktivnih sredstava i pripadajući postupci i sustavi
EA200801520A1 (ru) Химерные и гуманизированные антитела против человеческого интерлейкина-13 (il-13)
Donnelly et al. Clinical pharmacokinetics of inhaled budesonide
CN107998109A (zh) 药物组合物
WO2018134783A1 (en) Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants
KR101475262B1 (ko) 천식 치료에 사용되는 흡입용 복합 조성물
CN110062765A (zh) 包括il-13抗体的可吸入粉末组合物
US20130156823A1 (en) Excipient-free Aerosol Formulation
CN102327612A (zh) 一种稳定的人源化单克隆抗体制剂
CN101199845A (zh) 一种稳定的抗IgE人源化单抗制剂
Carlsen et al. Pharmaceutical treatment strategies for childhood asthma
Taki et al. The aerodynamic deposition of drugs from combination DPI formulations: The influence of particle size and drug-drug interactions
Mahmood et al. Anxiety: An Underlying Source of Cannabis Hyperemesis
US20160045396A1 (en) Pulmonary Delivery of Progestogen
US10954307B2 (en) Targeted delivery methods and compositions for antihistamines
Abdelhak African Journal of Pharmaceutical Sciences